---
figid: PMC7054735__10.1177_2042018820904016-fig1
figtitle: Therapeutic approaches for osteogenesis imperfecta
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC7054735
filename: 10.1177_2042018820904016-fig1.jpg
figlink: pmc/articles/PMC7054735/figure/fig1-2042018820904016/
number: F1
caption: Schematic representation of therapeutic approaches for osteogenesis imperfecta.
  (1) Bisphosphonates inhibit osteoclastic function. (2) Denosumab links RANKL, preventing
  the interaction with its receptor, RANK, on osteoclasts and osteoclasts precursors
  leading to inhibition of osteoclast formation and function. (3) Scl-Ab prevents
  binding of sclerostin to LRP5/6 and Frizzled coreceptors, thus inhibition of the
  Wnt/β-catenin signaling pathway. (4) Fresolimumab links TGF-β leading to beneficiary
  effects in bone remodeling. BPs, denosumab, and fresolimumab decrease bone resorption.
  Anti-sclerostin and fresolimumab increase bone formation.BPs, bisphosphonates; Fzld,
  Frizzled; HSC, hematopoietic stem cells; MSC, mesenchymal stroma cells; OPG, osteoprotegerin;
  RANK, receptor activator of nuclear factor κB; RANKL, receptor activator of nuclear
  factor κB ligand; Slc-Ab, sclerostin Antibodies; TGF-β, transforming growth factor-beta.
papertitle: New perspectives on the treatment of skeletal dysplasia.
reftext: Pauline Marzin, et al. Ther Adv Endocrinol Metab. 2020;11:2042018820904016.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9751198
figid_alias: PMC7054735__F1
figtype: Figure
redirect_from: /figures/PMC7054735__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7054735__10.1177_2042018820904016-fig1.html
  '@type': Dataset
  description: Schematic representation of therapeutic approaches for osteogenesis
    imperfecta. (1) Bisphosphonates inhibit osteoclastic function. (2) Denosumab links
    RANKL, preventing the interaction with its receptor, RANK, on osteoclasts and
    osteoclasts precursors leading to inhibition of osteoclast formation and function.
    (3) Scl-Ab prevents binding of sclerostin to LRP5/6 and Frizzled coreceptors,
    thus inhibition of the Wnt/β-catenin signaling pathway. (4) Fresolimumab links
    TGF-β leading to beneficiary effects in bone remodeling. BPs, denosumab, and fresolimumab
    decrease bone resorption. Anti-sclerostin and fresolimumab increase bone formation.BPs,
    bisphosphonates; Fzld, Frizzled; HSC, hematopoietic stem cells; MSC, mesenchymal
    stroma cells; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor
    κB; RANKL, receptor activator of nuclear factor κB ligand; Slc-Ab, sclerostin
    Antibodies; TGF-β, transforming growth factor-beta.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNFSF11
  - TNFRSF11A
  - MSC
  - SLC25A37
  - BTF3P11
  - TNFRSF11B
  - FUT1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - TGFB1
  - TGFB2
  - TGFB3
  - LRP5
  - CTNNB1
  - SOST
  - tnfrsf1b
  - msc
  - lrp5
  - ctnnb1
  - sost
---
